Molecular profiling company Caris Life Sciences partners with global biopharmaceutical company Incyte to enhance precision medicine strategies for Incyte’s cancer drug development program.
Under the terms of the agreement, Incyte will utilize Caris’ data analysis and insight capabilities to identify new biomarkers and optimize the clinical placement of its cancer treatment programs. For drugs that result from this collaboration, patients participating in Incyte-led clinical trials will undergo testing with Caris’ extensive tissue and liquid molecular profiling tests. Incyte will also use Caris’ biomarker-based patient selection clinical trials, which include the option to collaborate on developing companion diagnostics for programs involved in the partnership.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.